- 1 Title: Community Led Testing among People Who Inject Drugs: A community centered
- 2 model to find new cases of HIV and Hepatitis C in Nepal
- 3 Short title: Community Led HIV and Hepatitis C Testing among People Who Inject Drugs
- 4 Authors

10

17

18

26

30

- 5 Rajesh Didhiya<sup>1</sup>, Tara Nath Pokhrel<sup>2</sup>, Sudha Devkota<sup>2</sup>, Purusotam Raj Shedain<sup>2</sup>, Mukunda
- 6 Sharma<sup>4</sup>, Madan Kumar Shrestha<sup>2</sup>, Deepak Gyenwali<sup>1</sup>, Muhammad Imran<sup>4</sup>, Zakir Kadirov<sup>5</sup>,
- 7 Bhawani Prasad Dahal<sup>5</sup>, Amrit Bikram Rai<sup>1</sup>, Prawachan Kumar KC<sup>6</sup>, Sabir Ojha<sup>1</sup>, Khem
- 8 Narayan Pokhrel<sup>1</sup>\*

#### **Author Details**

- 1. National Association of People Living with HIV/AIDS in Nepal (NAP+N)
- 2. National Centre for AIDS and STD Control (NCASC)
- 3. National Public Health Laboratory (NPHL)
- 4. Save the Children, US
- 5. Save the Children, Nepal Country Office, KPRA Project
- 6. SPARSHA Nepal

## 19 \*Corresponding author

- 20 Khem Narayan Pokhrel, PhD,
- 21 Senior Research Fellow,
- National Association of People Living with HIV/AIDS in Nepal (NAP+N),
- House NO.: 174, Anek Marg, Baluwatar, Kathmandu-4, Nepal.
- 24 Contact phone: +977-01-4427459, 441783.
- 25 Email: pratikjee@gmail.com.

#### 27 Word Count

- 28 Abstract:300
- 29 Main text: 3694

### Abstract

31

32

39

#### Background

- People Who Inject Drugs (PWIDs) have sub-optimal HIV and HCV testing as the available
- testing services are inadequate in low and middle-income countries. We examined a model of
- Community-Led Testing (CLT) in Nepal, exploring the feasibility of HIV and HCV testing
- by trained lay service providers who had similar backgrounds to those of PWIDs. We also
- assessed the prevalence of HIV and HCV within this study population and the associated risk
- 38 factors among PWIDs.

#### Methods

- 40 A mix-method cross-sectional study was conducted among 1029 PWIDs in five major
- 41 districts of Nepal from July 2019 to February 2020. Trained PWID peers performed the
- 42 screening for HIV and HCV using Rapid Diagnostic Test (RDT) kits. Acceptability and
- feasibility of the testing was assessed. The participants' sociodemographic characteristics and
- 44 injecting and non-injecting risk characteristics were determined. The association of risk and
- 45 prevention characteristics with testing results were assessed using multiple logistic
- 46 regression.

#### 47 Results

- 48 PWIDs shared that the test providers were friendly and competent in counseling and testing.
- Of total PWIDs (n=1,029), 20.6% were HCV-positive and 0.2% were HIV-positive. HCV
- positivity was associated with needle sharing (AOR: 1.83, 95% CI: 1.27,2.64; p=0.001) and
- reuse of syringe/needle (AOR: 2.26; 95% CI: 1.34, 3.79; p=0.002). In addition, PWIDs were
- more likely to be HCV-positive who started opioid substitution therapy (OST) (AOR: 1.88,
- 53 95% CI: 1.26, 2.80, p=0.002) and attended the rehabilitation center (AOR: 1.66, 95% CI:
- 54 1.10, 2.53, p=0.017).

### Conclusions

55

- 57 This CLT model was found to be a novel approach of testing of HIV and HCV which was
- acceptable to PWIDs in Nepal and showed the high prevalence of HCV and its association
- with injecting-related risk behaviors and being users of OST and rehabilitation. The findings
- 60 highlight the need of community-led testing in hotspots, OST settings, and rehabilitation
- centers to screen new HIV and HCV infections.

62 Keywords: Community-led testing, HIV, HCV, Nepal, People who inject drugs

**Background** 

64

96

People who inject drugs (PWIDs) are a high-risk key population for contracting human 65 immunodeficiency virus (HIV) and Hepatitis C virus (HCV) infections (1-3). This group 66 accounts for the major proportion of HCV infections, globally (3). An estimated 2.3 million 67 people living with HIV are co-infected with HCV globally (3, 4). HCV-induced liver disease 68 69 has emerged as a major contributor to mortality and morbidity among people living with HIV 70 and are co-infected with HCV (5). 71 72 Current HIV and HCV testing services are inadequate in reaching the hard to reach high risk 73 key populations, particularly PWIDs, which has resulted in the under diagnosis of HIV and 74 HCV in low-and middle-income countries (LMICs) (6). Such gaps in testing may require 75 adopting alternative approaches and strategies to achieve the target for elimination of HIV and hepatitis C as public health threats by 2030 (6, 7). 76 77 Sero-prevalence studies conducted across various sites in Nepal have shown that HCV 78 prevalence among PWIDs is ranging from 21-38% in men and 3% in women in 2017. The 79 HIV/HCV co-infection was 2.5 to 7.4% in male PWIDs and 0.6% in female PWIDs 80 depending upon the study site in the country (8-10). Although Nepal has made progress in 81 improving accessibility of testing and treatment of HIV, an estimated 22% of the HIV-82 83 positive people remain undiagnosed (11). In addition, HCV testing services are only available in clinic-based settings, and PWIDs may not feel comfortable to seeking these testing 84 85 services from the facilities. PWIDs also face social and environmental challenges such as 86 poverty, homelessness, criminalization of drug injecting, lack of confidentiality, stigma, and discrimination (12, 13). 87 88 In order to overcome the prevailing barriers and bridge the gap in testing of HIV and HCV, 89 an innovative model of Community-Led Testing (CLT) was conceived, developed, and tested 90 in Nepal. In this model, trained In-reach Workers (IRWs) who had similar backgrounds to 91 those of PWIDs performed HIV and HCV screening using easy to use rapid diagnostic test 92 kits (RDTs) in the community, bringing testing services closer to those most at risk and who 93 might not otherwise have been tested (14). IRWs are the peer educators and lay service 94 providers to PWIDs who engaged in community service organizations (CSOs) in Nepal. 95

Community led or community driven approaches have increased acceptability and

97 effectiveness of the interventions employed to improve access to HIV services in some African countries (15-17). Such a community-led model was also found to be effective in 98 99 overcoming barriers and reaching the hard to reach, vulnerable and stigmatized key populations in HIV testing in Vietnam, and community home-based care support has 100 101 improved ART adherence in Nepal as well (18, 19). CLT model for HIV screening has been 102 implemented in Nepal since 2018. However, its acceptability and effectiveness is yet to be 103 examined (14). Moreover, there are no PWIDs focused HCV screening programs in 104 community settings. 105 This study aimed to examine the acceptability and feasibility of a CLT model of testing for 106 107 HIV and HCV among PWIDs and linking PWIDs to the available tratment, care, and support services. In addition, we assessed the prevalence of HIV, HCV, HIV/HCV co-infection and 108 the associated risk factors with HCV. 109 110 **Materials and Methods** 111 112 Study design 113 A mix-methods cross-sectional CLT study was designed and conducted among PWIDs in five major districts of Nepal. The qualitative approach explored in-depth knowledge on 114 115 acceptability and feasibility of this CLT model from clients' and providers' perspectives. While the quantitative approach was used to examine the risk characteristics of PWIDs and to 116 measure the prevalence of HIV and HCV, the study spanned from July 2019 to February 117 118 2020. Study setting, sample size and sampling strategy 119 120 We purposively selected five districts where an estimated 30% of all PWIDs in Nepal reside (18). Calculation of sample size was based on the current highest prevalence of HCV at 38% 121 according to the integrated biological and behavioural survey (IBBS) conducted in Nepal (9). 122 123 Sample size was calculated using G\*Power 3.1.9.6 for macOS, employing the 95% 124 confidence interval and 80% power, the calculated sample size was 980. In addition to taking the reference prevalence of HCV, injecting related characteristics and their association with 125 HCV positivity might need to be considered. Therefore, we increased the sample size to 126 127 1,029. We applied convenience sampling methods to reach the PWIDs peers through IRWs.

129

130

131

132

133134

135

136

137

138

139

140

141 142

143

144

145

146147

148

149

150

151

152

153

154

155

156

Data Collection Participants were recruited from satellite sites covering hot spots (e.g., the location or secret places where PWIDs generally meet to inject drugs), drop-in centres (DIC), needle/syringe exchange program locations, opioid substitution therapy (OST) sites, and rehabilitation centres. IRWs of the district-based CSOs were trained with five-days intensive training package for conducting CLTs, counselling, and data collection including the practices on KOBO data collection platform using Android tablets (20). Geographical tracking was also done to trace location of the participants from the office to the site where they were interviewed. Trained IRWs and peers were mobilized to identify and contact the participants. For qualitative data collection in-depth interviews (IDIs) were conducted among 70 participants from five study districts who were enrolled in CLT for screening HIV and HCV. Similarly, three Focus Group Discussions (FGDs) were conducted in three project sites among key CLT service providers covering IRWs, lab personnel, and counsellors. Trained professionals were mobilized to conduct IDIs and FGD sessions. Validated IDIs and FGD topic guides were used in the study. Participant inclusion criteria PWIDs were considered eligible for the study if they were current or past injecting drug users who, had injected drugs for at least 3 months before they were recruited in the study, and had never tested or tested negative for HIV and /or HCV within the 12 months preceding the survey. Participants aged 16 years and above were enrolled. All the participants meeting inclusion criteria had provided consent to enrol in the study and to provide information. Therefore, no participants from the sample were excluded in the study. Study variables Socio-demographic information: Participants' age, ethnicity, educational status, marital status, gender, and occupation, history of HIV and HCV testing were recorded adopting the survey instruments of the Nepal Demographic Health Survey, 2016 (21). **Injection related risk characteristics:** We adopted the questionnaires about the injection related risk characteristics covering needle sharing behaviors and other equipment sharing as defined by the IBBS study in Nepal (8, 9).

159

163

164

165

166

167

169

**HIV** and **HCV** risk factors: The risk factors were adopted from the Nepal IBBS study covering tattoos or body piercing, having sexual partner with status of HIV or with chronic 158 hepatitis C/HIV, condom use, and weekly alcohol use (9). 160 **Prevention activities:** We interviewed the participants about their exposure to peereducation interventions, opioid substitution therapy, rehabilitation, needle and syringe 161 162 exchange programs following the harm reduction programs activities of National Center for AIDS and STDs Control (NCASC). Biological test: HCV and HIV screening used RDTs. Alere Determine<sup>TM</sup> HIV-1/2 and SD BIOLINE HCV RDTs were used for screening HIV and HCV, respectively, using blood samples from finger pricks in the satellite sites covering various hotspots, OST clinics, drop-in centers, and rehabilitation centers. Trained and certified IRWs performed screening of HIV and HCV of PWIDs and recorded clients' information including behavioural 168 charactersitics and test results in client report form (CRF) at satellite sites. 170 **Qualitative information:** Qualitative data collection methods such as FGDs and IDIs were applied to test the thematic topics: acceptability, feasibility, challenges/bottlenecks and 171 172 unplanned effect of CLT.

Figure 1 Algorithm : The HIV/HCV CLT model in Nepal (See attached image)

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

Data analysis Quantitative data were analyzed using STATA version 14.0. Descriptive analyses were done covering client's characteristics and the prevalence of HIV, HCV and HIV/HCV co-infection stratified by gender. Logistic regression analysis was applied to identify the association of socio-demographic characteristic and risk related characteristics with the prevalence of HCV. Results of HIV testing precluded meaningful analyses, since the number was so low. The qualitative interviews and focus groups were transcribed and translated into English. The contents of transcripts were analyzed based on the pre-defined and emerging themes and subthemes. We used MAXQDA 2020 (22) software for data coding, data sorting and extracting quotes according to theme. Ethical consideration As PWIDs are vulnerable, socially stigmatized and criminalized for drug use in Nepal, the study was conducted maintaining optimal ethical and human rights standards throughout the study period. Written infomed consent was taken from all the participants before enrolling them in the study. Similarly, written assent was taken from senior peers of the participants below 18 years of age. Ethical approval was obtained from ethical review board of the Nepal Health Research Council (NHRC) [Reg No. 552/2019] prior to the commencement of the fieldwork. Participants, who tested as HIV and HCV negative were counselled on safer behaviors and referred to harm reduction programs. Participants identified as either HIV and/or HCV positive were referred to the demonstration sites for counseling, HIV confirmatory test, linkages for HIV treatment, care and support, and to collect blood sample for HCV RNA/PCR. Participants identified as HCV positive were linked to post-test counselling services, liver fibrosis assessment through APRI scoring and referred to a hepatologist for appropriate follow up.

**Results** 

216

Sociodemographic characteristics of Participants 217 218 Of total participants (n=1,029), 91.6% were men and 8.4% were women. Mean ages were 219 28.6 (SD=7.0) years for men and 23.4 (SD=3.7) years for women. Proportion of women in the age group of 16-24 years was 66.3% and that of men was 34.3%. The majority of 220 221 participants were Janajati (Disadvantaged Janajati: 26.3% and Advantaged Janajati: 35.6%). About 63.1% of men and 75.6% of women were unmarried. Nearly two thirds (61.7%) of the 222 223 participants were unemployed. Those who had ever enrolled in school, their mean year of schooling was 9.8 (SD=2.4) (Table 1). 224 225 Risk related characteristics of participants by gender 226 Of total (n=1029), 56.8% were current drug users. More than half (51.6%) of the participants 227 reported that they had never tested for HIV. Regarding risk behaviors, 75.0% reported that they reused needles, 50.5% shared needles/syringes, and 29.9% shared a 228 229 cooker/vial/container. About 55% of the participants were recruited from hotspots and 29% 230 were from rehabilitation centers. About 61.0% of the participants had an injection history of more than five years, and 43.6% 231 232 reported that they had injected in the last seven days. Regarding needle/syringe sharing, 50% 233 of men and 57.0% of women reported that they shared needles. In addition, 29.9% of 234 participants reported that they had a practice of sharing a cooker/vial/container. Regarding other risk characteristics, 30.4% of men and 5.8% of the women consumed alcohol weekly, 235 236 and 57.0% of the total participants had done tattooing. Nearly half of the women (47.7%) 237 responded that they did not know their partner's HIV status, and 37.5% of men did not know 238 their partner's status. While having sex with regular partner/sex workers, 57.1% reported that they always used condoms (Table 2). 239 240 Past testing, prevention exposure according to gender 241 Of the total, 17% of the participants reported that they had HCV test at least 12 months prior to the survey. Regarding the reason for not testing for HCV, 43.0 % reported fear of 242 243 confidentiality breaches and 39.5% were not aware of the risk of HCV and HIV. Other 244 reasons were screening is too expensive (23.5%), carelessness within themselves (18.0%), 245 and no treatment is available (11.5%). About 10.5% reported that they did not know the 246 testing facilities. About 52.9% of men and 62.8% of women participated in the IRW provided 247 harm reduction intervention, 28.1% started OST, and 63.2% attended a rehabilitation center. About 69.6% reported that they had participated in needle/syringe exchange program. About 248 249 61.8% reported that they felt stigma from family; a higher proportion of men compared to women (63.7% vs. 40.7%) felt stigma from family. 250 251 The overall prevalence of HCV in this sample was 20.6% (men=21.2%; women=14.0%). All 252 HCV-positive participants were referred to demonstration sites to collect blood samples and 253 the samples were sent to the National Public Health Laboratory [NPHL] for HCV RNA/PCR test. Only two men (0.2%) tested HIV positive and had HCV positive test as well. HIV-254 255 positive samples were sent for confirmatory tests using three RDTs as per national HIV testing algorithm. Both participants were confirmed as HIV positive, and both were linked to 256 ART services. Among those who tested for HCV RNA (n=203), 68% had HCV RNA (IU/ml) 257 count ranging from 65 to 1000000 (Table 3). 258 259 Descriptive analysis of socio-demographic and risk characteristics and their association with HCV screening result 260 Significantly higher proportion of participants in the age group of 25-50 years were HCV 261 262 positive (77.4%) compared with those in the age group of 16-24 years and above 50 years (p<0.001). A higher proportion of married participants were HCV positive (57.1%) 263 compared to unmarried and divorced/separated participants (p<0.001). HCV negative 264 265 participants had a higher mean number of years of schooling than HCV positive [negative mean=10.1 (SD=2.2) vs. positive: mean=8.9 (SD=2.7), p<0.001]. 266 A higher proportion of participants who reported needle sharing (58.0%) were HCV positive 267 compared to those who did not share needles (p=0.014). In addition, a higher proportion 268 participant who shared a cooker/vial/container were HCV positive compared to those who 269 270 did not share (positive: 37.3% vs. negative: 28.0%, p=0.009). In addition, there was a significant difference on HCV positive and HCV negative results between those who 271 272 reported re-use of needle/syringe compared with who did not reuse needle and syringes. 273 (positive: 86.2% vs. negative: 72.1%, p<0.001). 274 Regarding risky sexual behaviors, those participants who had sexual contact with a person of unknown HIV status had higher proportion of HCV positive results (positive: 30.2% vs. 275 negative: 20.3%, p=0.002) compared with participants who had no sexual contact or knew 276 277 the HIV status of their partner. Those participants who always used condoms had a low 278 proportion of HCV positive results compared to those who did not use condoms and used

279 them only sometimes (positive: 37.4% vs. negative: 50.6%, p=0.001). Also, PWIDs with tattoos had a higher prevalence of HCV positive than those without tattoos(positive: 67.5% 280 281 vs. negative: 54.2%, p<0.001). Similarly, participants who consumed alcohol weekly had a 282 higher proportion of HCV positive results relative to those who did not consume alcohol 283 weekly (positive: 75.9% vs. negative: 67.9%, p=0.024). (Table 4). Descriptive analysis of risk behavior and prevention exposure associated with HCV 284 285 screening result 286 A higher proportion of HCV positive PWIDs had started OST compared to HCV negative (positive: 46.2% vs. negative: 23.4%, p<0.001). Rehabilitation participants had a higher 287 proportion of HCV positive test results (positive: 76.4% vs. negative: 59.7%, p<0.001) 288 289 relative to non-participants, and a higher proportion of HCV positive results were found among subjects who were involved in needle/syringe exchange programs (positive: 75.9% vs. 290 291 negative: 67.9%, p=0.024). (Table 5). Multivariate analysis of injecting risk behavior, prevention exposure associated with 292 **HCV** screening results 293 294 Analyses were performed controlling for age, sex, marital, education level, tattooing, and 295 participation in a needle/syringe exchange program. Higher odds of HCV positive results were found in participants who had practice of needle sharing (AOR: 1.83, 95% CI: 296 1.27,2.64, p=0.001) and reuse of syringes/needles (AOR: 2.26, 95% CI: 1.34, 3.79, p=0.002). 297 In addition, HCV positive results were positively associated with those who started OST 298 299 (AOR: 1.88, 95% CI: 1.26, 2.80, p=0.002) and attended a rehabilitation center (AOR: 1.66, 95% CI: 1.10, 2.53, p=0.017.) (Table 6). 300 301 **Qualitative findings** 302 Feasibility of CLT IRWs shared their experience 303 "I never thought that I would have this much skills and perceptions about the 304 in counseling and testing. The training made me feasibility of community led 305 more skilled in testing procedures. I felt myself testing. Doing RDT was 306 proud to reach my peer PWIDs who never get 307 convenient for them because tested. It is really the rewarding job testing by the community for the community" ---20's IRW 308 they found that PWIDs were 309 ready to get tested and agreed to be tested by their peers. They shared the positive and encouraging aspect of this model was 310

313

314

315

316

317

318

319

320

321

322

323

324

325

326 327

328

329

330

331

332

333

334

335

336

337

338 339

340

341

342

"testing by the community for the community." The trained IRWs shared that they developed confidence as they had proper skill for procedure through the training and having received a certificate from a government authority. Another aspect shared by the trained peer was that they felt empowered and employed to test their community for the benefit of the community. The testing was easier for them as they found willingness among the peer PWIDs to get tested and refer their friends for testing for HIV and HCV. Acceptability of CLT The community led testing was acceptable among the participants as they reported that they found friendly behavior among test providers and perceived that the trained test providers had competence in counseling and testing. In "I felt praised to meet my friend in the usual addition, participants reported that they injecting site. Got very much impressed with were happy to have immediate test his pre-test counseling and his confidence in results and having the testing place of testing procedure. Relieved to have result instantly". - 30's PWID their choice. Regarding privacy and confidentiality, PWIDs felt assured about the privacy maintained by the IRWs for testing. They had also greater trust toward the interviewers and test takers in the field. They had trust on pre-counselling and testing, and felt that their community are the service provider for the benefit of their diagnosis. Their perception was that they received exceptional support from their peers in testing and counseling from trained IRWs. Bottlenecks/challenges A few IRWs perceived that it "I don't know how we could overcome the interference was difficult for them in of police as our protocol says we can test in the hotspots. finding PWIDs who have not I never discouraged from the incident of some sites as we encountered the police during testing. I kept on tested. Another problem that testing as I felt it is helping to the community" ---20's the trained peer said that in **IRW** some cases they had difficulty in finding a private testing venue because some were feeling uncomfortable because police might interfere- as drug use is treated as a criminal act in Nepal. However, they never got discouraged and kept on going for testing and finding the community. Some thought that they had problems convincing the peers about the treatment available for HCV infection if they

344

345

346

347 348

349

350

351 352

353

354

355

356

357

358

359

360 361

362

363

364

365 366

367

368 369

370

371 372

373

tested positive. However, they referred positive participants for the consultation with the hepatologist. Discussion This study is the novel of its kind in Nepal, which applied CLT model to screen the hidden PWIDs affected by HIV and HCV. The model was proven a feasible testing approach for HIV and HCV in a low-resource setting such as Nepal and was acceptable by PWIDs. The lay test providers and peers/IRWs had confidence in reaching, providing counseling, maintaining the privacy of PWIDs and testing in the satellite sites. The test providers also felt empowered as they were doing something for their own community: "Testing by the community for the community". Although a few service providers had some difficulties in finding private testing locations and felt fear of interference from the police, they were able to reach the PWIDs in convenient places and provide testing upon request. In addition, PWIDs shared that the test providers were friendly and were competent in counseling and testing. They shared that the best part of the CLT was that they received the result instantly and were referred for further services. This model can be one of the approaches to overcome the access barriers for PWIDs for seeking services from clinical settings (13, 18, 23). This study found that 0.2% of participants had HIV and 20% had HCV. The lower rate of HIV could be due to better utilization of testing services and their exposure to prevention services. Also, those who had HIV testing prior to 12 months of the survey were not included in this model. The reliability of testing was promising as the result accuracy was 100% while performing confirmatory testing in National Public Health Laboratory (NPHL). HCV positivity result is in line with the IBBS study findings, which has shown the prevalence ranging from 18.8 to 38% (8-10). The true prevalence of HCV among PWIDs could be even higher than that revealed by the study if the criteria "never tested or tested HCV negative at least for 1ast 12 months" were not used. This statement is supported by the findings of a study conducted in 2015 which had shown almost 50% of the PWIDs with HCV-RNA sought services from organized institutions (24). PWIDs represent 3% of the total cases of HIV in Nepal and HIV incidence was 0.03% in 2020 and the prevalence among adult population was 0.13% (11). The study results indicated that PWIDs who were not reached by the ongoing program for HIV screening and could be reached through this peer-led approach (16, 18) although detection of HIV is fairly low. This

375

376

377

378

379 380

381

382

383 384

385

386

387 388

389

390

391 392

393

394

395

396 397

398

399 400

401

402

403 404 405 CLT approach would be complementary to the current HIV/HCV screening services, as the PWIDs feel stigma and fear of confidentiality breaches in the health facilities that have resulted in non-availability or inaccessibility of the screening services (13, 18, 23). This study also found that needle sharing and needle reuse were major risk factors for HCV infection. Reuse of needles and needle/ syringe sharing may have increased the risk of vulnerability of transmission. In addition, HCV positivity rate was found to be high among PWIDs who started their OST and attended rehabilitation center. Participants seeking services from institutions may have history of years of injecting drug use before enrollment in the services and might have not used the available testing for HCV services with a fear of lack of treatment availability of HCV. Longer duration of exposure is positively associated with HCV infection and the longer duration increases the repeated high risk behaviors such as needle sharing, re-use of needles, and unsafe sexual behaviors (24, 25). Despite the major significance of this CLT model, the study has two major limitations. First, due to nature of screening hidden PWIDs, we applied non-probability sampling led by peer PWIDs. This may affect the generalizability of the results. However, IRWs were reaching every satellite site with the mapping so that they would be able to reach more hidden and non-diagnosed cases. Second, we were not able to assess the factors associated with HIVpositivity because of the low prevalence in the screened populations. However, the risk characteristics of HCV and HIV could be assumed similar such as needle sharing and sharing of injecting preparation materials. **Conclusion:** This CLT study has shown that peer lay test providers were well accepted by PWIDs for counseling and testing. This model has become promising to test for HCV and HIV among PWIDs in their convenient sites. Also, the study shows that risk behaviour such as needle reuse and needle sharing led to HCV infection. Moreover, higher proportion of PWIDs in rehabilitation center and on OST were also tested positive for HCV. Therefore, this study highlights the expansion of this model to screen for both HCV and HIV together in other parts of the country and similar settings, where PWIDs encounter barriers to access to testing services.

407 408

409

410

411

412

413

414

415

416

417 418

419 420 421

422

423

424

425

426

427

428

429

430

431

432

437

Acknowledgments We acknowledge the CSOs involved in this research project SPARSHA Nepal-Kathmandu, Community Support Group-Kaski, and Nirnaya-Chitwan. We would like to thank the IRWs, who successfully conducted the testing and field work for quantitative data collection and qualitative researchers who conducted IDIs and FGDs. We owe to all 1029 PWIDs who successfully and willingly participated in this study, provided information, agreed for the test of HIV and HCV in the satellite places. We have also number of consultants to acknowledge who provided the inputs in design. Further, we would like to acknowledge the support received from the administrative, logistic, and financial staffs of Save the children, NCASC, NAP+N, and NPHL. **Author Contributions** Conceptualization: Rajesh Didiya, Tara Nath Pokhrel, Zakir Kadirov, Purusotam Raj Sedai, Mukunda Sharma, Madan Kumar Shrestha, Deepak Gyenwali, Bhawani Prasad Dahal, Amrit Bikram Rai, Khem Narayan Pokhrel **Data curation:** Deepak Gyenwali, Khem Narayan Pokhrel Formal analysis: Khem Narayan Pokhrel, Deepak Gyenwali Supervision: Rajesh Didiya, Deepak Gyenwali, Tara Nath Pokhrel, Khem Narayan Pokhrel Validation: Tara Nath Pokhrel, Bhawani Prasad Dahal, Zakir Kadirov, Khem Narayan Pokhrel Manuscript preparation and finalization: Khem Narayan Pokhrel Manuscript – review & editing: Rajesh Didiya, Tara Nath Pokhrel, Zakir Kadirov, Muhammad Imran, Purusotam Raj Sedai, Mukunda Sharma, Madan Kumar Shrestha, Deepak Gyenwali, Bhawani Prasad Dahal, Amrit Bikram Rai, Sabir Ojha, Prawachan Kumar KC

#### References

- 1. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global
- prevalence of injecting drug use and sociodemographic characteristics and prevalence of
- 441 HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. The
- 442 Lancet Global Health. 2017;5(12):e1192-e207.
- 2. Rashti R, Alavian SM, Moradi Y, Sharafi H, Bolbanabad AM, Roshani D, et al. Global
- prevalence of HCV and/or HBV coinfections among people who inject drugs and female
- sex workers who live with HIV/AIDS: a systematic review and meta-analysis. Archives
- of Virology. 2020:1-12.
- 3. WHO. Global hepatitis report 2017: World Health Organization 2017. Report No.:
- 9241565454.
- 4. WHO. HIV/AIDS Key facts. 2018:1-7. Available from https://www.who.int/news-
- room/fact-sheets/detail/hiv-aids. Accessed on September 16, 2020.
- 5. Poudel KC, Palmer PH, Jimba M, Mizoue T, Kobayashi J, Poudel-Tandukar K.
- Coinfection with hepatitis C virus among HIV-positive people in the Kathmandu Valley,
- 453 Nepal. Journal of the International Association of Providers of AIDS Care (JIAPAC).
- 454 2014;13(3):277-83.
- 455 6. WHO. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral
- hepatitis: World Health Organization. 2016.
- 7. WHO. Global health sector strategy on HIV 2016-2021. Towards ending AIDS: World
- 458 Health Organization. 2016.
- 8. NCASC. Integrated Biological and Behavioral Surveillance (IBBS) Survey among
- People Who Inject Drugs (PWID) in Kathmandu Valley. Kathmandu Nepal.
- 461 Kathmandu, Nepal. 2017.
- 462 9. NCASC. Integrated Biological and Behavioural Surveillance (IBBS) Surveys among
- People Who Inject Drugs (PWID) in Eastern Terai Highway Districts. Kathmandu,
- Nepal: National Center for AIDS and STDs Control. 2017.
- 465 10. NCASC. Integrated Biological and Behavioural Surveillance (IBBS) Surveys among
- People Who Inject Drugs (PWID-Male) in Pokhara Valley: National Center for AIDS
- and STDs Control. 2017.
- 468 11. HIV Epidemic Update of Nepal [database on the Internet]2020 [cited 12.15.2020].
- 469 Available from: http://www.ncasc.gov.np/WAD2020/Factsheet-2020-S.pdf.

- 470 12. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global
- epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of
- systematic reviews. The Lancet. 2011;378(9791):571-83.
- 13. Barocas JA, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP. Barriers and
- facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-
- methods study. Harm reduction journal. 2014;11(1):1-8.
- 14. NCASC. National Guidelines Community-Led HIV Testing 2017 Nepal. Kathmandu
- Nepal: National Center for AIDS and STDs Control; 2017.
- 478 15. Ndyomugyenyi R, Kabali AT. Community-directed interventions for integrated delivery
- of a health package against major health problems in rural Uganda: perceptions on the
- strategy and its effectiveness. International health. 2010;2(3):197-205.
- 481 16. Indravudh PP, Fielding K, Kumwenda MK, Nzawa R, Chilongosi R, Desmond N, et al.
- Community-led delivery of HIV self-testing to improve HIV testing, ART initiation and
- broader social outcomes in rural Malawi: study protocol for a cluster-randomised trial.
- 484 BMC infectious diseases. 2019;19(1):814.
- 485 17. Sharma M, Barnabas RV, Celum C. Community-based strategies to strengthen men's
- engagement in the HIV care cascade in sub-Saharan Africa. PLoS medicine.
- 487 2017;14(4):e1002262.
- 488 18. Nguyen VTT, Phan HT, Kato M, Nguyen QT, Le Ai KA, Vo SH, et al. Community ☐ led
- 489 HIV testing services including HIV self□ testing and assisted partner notification
- 490 services in Vietnam: lessons from a pilot study in a concentrated epidemic setting.
- Journal of the International AIDS Society. 2019;22:e25301.
- 492 19. Pokhrel KN, Sharma VD, Pokhrel KG, Neupane SR, Mlunde LB, Poudel KC, et al.
- Investigating the impact of a community home-based care on mental health and anti-
- retroviral therapy adherence in people living with HIV in Nepal: a community
- intervention study. BMC infectious diseases. 2018;18(1):263.
- 496 20. KOBO Tool Box Cambridge, MA: The Harvard Humanitarian Initiative; 2019 [cited
- 497 2021 10.11.2020]; Available from: https://www.kobotoolbox.org/.
- 498 21. MOHP Nepal. Nepal Demographic and Health Survey 2016. Kathmandu: Ministry of
- 499 Health 2017.
- 500 22. Software V. MAXQDA 2020. 2019.
- 501 23. Swan D, Long J, Carr O, Flanagan J, Irish H, Keating S, et al. Barriers to and facilitators
- of hepatitis C testing, management, and treatment among current and former injecting
- drug users: a qualitative exploration. AIDS patient care and STDs. 2010;24(12):753-62.

24. Kinkel H-T, Karmacharya D, Shakya J, Manandhar S, Panthi S, Karmacharya P, et al. Prevalence of HIV, hepatitis B and C infections and an assessment of HCV-genotypes and two IL28B SNPs among people who inject drugs in three regions of Nepal. PLoS One. 2015;10(8).
25. Poudel KC, Poudel-Tandukar K, Yasuoka J, Joshi AB, Jimba M. Correlates of sharing injection equipment among male injecting drug users in Kathmandu, Nepal. International Journal of Drug Policy. 2010;21(6):507-10.

## 514 Tables

515

516

## Table 1: Socio-demographic characteristics of participants by gender

Characteristics	Men (n=943)	Women (n=86)	<b>Total</b> (n, %)
	(n, %)	(n, %)	
Age (mean, SD)	28.6 (7.0)	23.4 (3.7)	28.2 (7.0)
Age groups			
16-24 years	323 (34.3)	57 (66.3)	380 (36.9)
25-50 years	610 (64.7)	29 (33.7)	639 (62.1)
Above 50 years	10 (1.0)	0 (0.0)	10 (1.0)
Ethnicity			
Dalit	81 (8.6)	8 (9.4)	89 (8.7)
Disadvantaged Janajati	245 (26.0)	25 (29.0)	270 (26.3)
Disadvantaged non-Dalit Terai	2 (0.2)	1 (1.2)	3 (0.3)
Religious minorities (Muslim)	8 (0.9)	0 (0.0)	8 (0.8)
Advantaged Janajati	340 (36.1)	26 (30.2)	366 (35.6)
Upper caste (Brahmin/Chhetri)	266 (28.2)	26 (30.2)	292 (28.3)
Marital status			
Unmarried	595 (63.1)	65 (75.6)	660 (64.1)
Married	339 (36.0)	21 (24.4)	360 (35.0)
Divorced/separated	9 (1.0)	0 (0.0)	9 (0.9)
Occupation			
Unemployed	562 (59.6)	73 (84.9)	635 (61.7)
Professional/technical/Managerial	7 (0.7)	0 (0.0)	7 (0.7)
Labor	96 (10.2)	2 (2.3)	98 (9.5)
Business	134 (14.2)	6 (7.0)	140 (13.6)
Agriculture	8 (0.9)	0 (0.0)	8 (0.8)
Student	52 (5.5)	3 (3.5)	55 (5.3)
Others	84 (8.9)	2 (2.3)	86 (8.4)
<b>Education level</b>			
Illiterate	0 (0.0)	8 (0.9)	8 (0.8)
Literate but not formal education	12 (1.3)	4 (4.7)	16 (1.6)
Formal education received	923 (97.9)	82 (95.4)	1005 (97.7)
Mean (SD) schooling years (n=1005)	9.4 (2.4)	9.8 (2.4)	9.8 (2.4)

## 517 Table 2: Risk characteristics of participants by gender

Characteristics	Men	Women	Total
	(n=943, %)	(n = 86, %)	(n=1029,%)
Ever drug use			
Current	531 (56.3)	54 (62.8)	585 (56.8)
Past	412 (43.7)	32 (37.2)	444 (43.2)
Last test of HIV Done			
Never	490 (52.0)	41 (47.7)	531 (51.6)
Before 12 months	453 (48.0)	45 (52.3)	498 (48.4)
Risk behavior (multiple response)			

Shared a needle	471 (50.0)	49 (57.0)	520 (50.5)
Shared a cooker/vial/container	288 (30.5)	20 (23.3)	308 (29.9)
Shared a cotton/filter/rinse water	43 (4.6)	1 (1.2)	44 (4.3)
Re-used syringe/needle	717 (76.0)	55 (64.0)	772 (75.0)
Not shared	30 (3.2)	0 (0.0)	30 (2.9)
Type of satellite			
DIC	33 (3.5)	1 (1.2)	34 (3.3)
Hotspots	516 (54.7)	50 (58.1)	566 (55.0)
OST Clinic	71 (7.5)	2 (2.3)	73 (7.1)
Rehabilitation center	272 (28.8)	31 (36.1)	303 (29.5)
ART Clinic	2 (0.2)	0 (0.0)	2 (0.2)
Others	49 (5.2)	2 (2.3)	51 (5.0)
Injecting duration			
<=1 year	25 (2.7)	7 (8.1)	32 (3.1)
Between one year and five years	323 (34.3)	46 (53.5)	369 (35.9)
More than five years	595 (63.1)	33 (38.4)	628 (61.0)
Last injected (days)			
<=7 days	417 (44.2)	32 (37.2)	449 (43.6)
8-30 days	109 (11.6)	22 (22.6)	131 (12.7)
31 days or more	417 (44.2)	32 (37.2)	449 (43.7)
Weekly alcohol use			
Yes	287 (30.4)	5 (5.8)	292 (28.3)
No	656 (69.6)	81 (94.2)	737 (71.6)
Tattoo			
Yes	546 (57.9)	40 (46.5)	586 (57.0)
No	397 (42.1)	46 (53.5)	443 (43.0)
Partner status			
HIV-positive	2 (0.2)	0 (0.0)	2 (0.2)
Hepatitis C	2 (0.2)	1 (1.2)	3 (0.3)
Don't know	354 (37.5)	41 (47.7)	395 (38.4)
None	585 (62.0)	44 (51.2)	629 (61.1)
Condom use with casual			
partners/SWs			
Never			51 (5.0)
Always			588 (57.1)
Sometimes			326 (31.7)
Never had sex with SWs			64 (6.2)

## Table 3: Past testing, prevention, stigma, and current testing results by gender

Characteristics	Men	Women	Total (n=1029)
	(n=943,%)	(n=86,%)	
Past HCV test			
Yes	170 (18.0)	5 (5.8)	175 (17.0)
No	773 (82.0)	81 (94.2)	854 (83.0)
Reason for not testing HCV (multiple			
response)			
Not aware of the risk	299 (38.6)	41 (50.6)	340 (39.7)
Don't know about the testing	87 (11.2)	3 (3.7)	90 (10.5)

facilities			
Testing facility is too far	18 (2.3)	1 (1.2)	19 (2.2)
Fear of stigma in the facility	60 (7.7)	5 (6.2)	65 (7.6)
Fear of confidentiality	338 (43.6)	30 (37.0)	368 (43.0)
Screening is too expensive	189 (24.4)	12 (14.8)	201 (23.5)
No treatment is available	92 (11.9)	6 (7.4)	98 (11.5)
Carelessness	148 (10.7)	6 (0.7)	154 (18.0)
Participated in IRW intervention	, ,		
Yes	499 (52.9)	54 (62.8)	553 (53.7)
No	444 (47.1)	32 (37.2)	476 (46.3)
OST started			
Yes	278 (29.5)	11 (12.8)	289 (28.1)
No	664 (70.5)	75 (87.2)	739 (71.9)
Attended in Rehabilitation center			
Yes	600 (63.6)	50 (58.1)	650 (63.2)
No	343 (36.8)	36 (41.9)	379 (36.8)
Participated in needle/syringe			
exchange program			
Yes	653 (69.3)	63 (73.2)	716 (69.6)
No	290 (30.8)	23 (26.7)	313 (30.4)
Stigma			
Stigma from family	601 (63.7)	35 (40.7)	636 (61.8)
Stigma in the health facility	64 (6.8)	1 (1.2)	65 (6.3)
Stigma in office/work	42 (4.5)	0 (0.0)	42 (4.1)
Not felt stigma	325 (34.5)	51 (59.3)	376 (36.5)
Stigma felt in other places	38 (4.0)	1 (1.2)	39 (3.8)
HCV screening result			
Positive	200 (21.2)	12 (14.0)	212 (20.6)
Negative	743 (78.8)	74 (86.0)	817 (79.4)
HIV screening result			
Positive	2 (0.2)	0(0.0)	2 (0.2)
Negative	941 (99.8)	86 (100.0)	1027 (99.8)
HIV confirmatory test 3RDT	2 (100.0)	0 (0.0)	2 (100.0)
<b>proposed</b> (yes)[as per national HIV			
testing algorithm]			
HCV RNA (IU/ml) (n=203)			
<65			61 (30.0)
65 to 1000000			138 (68.0)
>1000000			4 (2.0)

# Table 4: Descriptive analysis of socio-demographic and risk characteristics on HCV screening results

Characteristics	HCV positive	HCV negative	p-value
	(n=212, %)	(n=817, %)	
Age groups			< 0.001
16-24 years	40 (18.9)	340 (41.6)	
25-50 years	164 (77.4)	475 (58.2)	
Above 50 years	8 (3.8)	2 (0.2)	

Gender			0.111
Men	200 (94.3)	743 (90.9)	
Women	12 (5.7)	74 (9.1)	
Marital status			< 0.001
Unmarried	88 (41.5)	572 (70.0)	
Married	121 (57.1)	239 (29.3)	
Divorced/separated	3 (1.4)	6 (0.7)	
Mean (SD) schooling years (n=1005)	8.9 (2.7)	10.1 (2.2)	< 0.001
Needle Sharing			0.014
Yes	123 (58.0)	397 (48.6)	
No	89 (42.0)	420 (51.4)	
Shared a cooker/vial/container			0.009
Yes	79 (37.3)	229 (28.0)	
No	133 (62.7)	588 (71.9)	
Reused needle/syringe			< 0.001
Yes	183 (86.2)	589 (72.1)	
No	29 (13.7)	228 (27.9)	
Sexual contact with person with			0.002
HIV unknown status (yes)			
Yes	64 (30.2)	165 (20.3)	
No	148 (69.8)	647 (79.7)	
Condom use			0.001
No	44 (20.9)	162 (19.6)	
Always	79 (37.4)	413 (50.6)	
Sometimes	88 (41.7)	241 (29.5)	
Tattoo done			0.001
No	69 (32.6)	374 (45.8)	
Yes	143 (67.5)	443 (54.2)	
Weekly alcohol consumption			0.024
No	51 (24.0)	262 (32.1)	
Yes	161 (75.9)	555 (67.9)	

## Table 5: Descriptive analysis of risk behavior and prevention exposure with HCV screening result

Characteristics	HCV positive	HCV Negative	p-value
	(n, %)	( <b>n</b> , %)	
Participated in peer			0.869
education/IRW intervention			
No	97 (45.8)	379 (46.4)	
Yes	115 (54.3)	438 (53.6)	
Started OST			< 0.001
No	114 (53.8)	625 (76.6)	
Yes	98 (46.2)	191 (23.4)	
Attended rehabilitation			< 0.001
center			
No	50 (23.6)	329 (40.3)	
Yes	162 (76.4)	488 (59.7)	
Participated in			0.024

needle/syringe exchange			
program			
No	51 (24.1)	262 (32.1)	
Yes	161 (75.9)	555 (67.9)	

## Table 6: Multivariate analysis of injecting risk behavior, prevention exposure with HCV

#### 524 screening results

523

526

	Adjusted odds		p-value
Characteristics	Ratio <sup>1</sup>	95% CI	
Needle sharing	1.83	1.27, 2.64	0.001
Reused syringe/needle	2.26	1.34, 3.79	0.002
OST started	1.88	1.26, 2.80	0.002
Attended Rehabilitation Center	1.66	1.10, 2.53	0.017
Participated needle syringe exchange			
program	0.67	0.42, 1.08	0.108
Tattooing	1.18	0.76, 1.82	0.455
Age	1.10	1.05, 1.22	< 0.001
Sex (male)	0.52	0.25, 1.11	0.093
Marital status (married)	0.84	0.55, 1.22	0.427
Educational level	0.79	0.73, 0.85	< 0.001

<sup>&</sup>lt;sup>1</sup>Adjusted for age, sex, marital, education level, tattooing, participated in needle syringe exchange program,

needle sharing, need syringe/needle, OST started, attended rehabilitation center

